Precore mutation of hepatitis B virus may be associated with low breakthrough rate following long-term lamivudine therapy in patients with chronic hepatitis B

被引：0
|
作者：
Ryu, SH [1 ]
Chung, YH [1 ]
Choi, MH [1 ]
Kim, JA [1 ]
Shin, JW [1 ]
Jang, MK [1 ]
Park, NH [1 ]
Lee, HC [1 ]
Lee, YS [1 ]
Suh, DJ [1 ]
机构：
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
来源：
HEPATOLOGY | 2002年 / 36卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1917
引用
收藏
页码：642A / 642A
页数：1
相关论文
共 50 条
  • [31] Long-term effects of lamivudine treatment in Japanese chronic hepatitis B patients
    Masayuki Murata
    Norihiro Furusyo
    Mami Unno
    Eiichi Ogawa
    Kazuhiro Toyoda
    Hiroaki Taniai
    Hachiro Ohnishi
    Jun Hayashi
    World Journal of Gastroenterology, 2011, 17 (24) : 2945 - 2952
  • [32] Long-term effects of lamivudine treatment in Japanese chronic hepatitis B patients
    Murata, Masayuki
    Furusyo, Norihiro
    Unno, Mami
    Ogawa, Eiichi
    Toyoda, Kazuhiro
    Taniai, Hiroaki
    Ohnishi, Hachiro
    Hayashi, Jun
    WORLD JOURNAL OF GASTROENTEROLOGY, 2011, 17 (24) : 2945 - 2952
  • [33] Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B
    Tatulli, I
    Francavilla, R
    Rizzo, GL
    Vinciguerra, V
    Ierardi, E
    Amoruso, A
    Panella, C
    Francavilla, A
    JOURNAL OF HEPATOLOGY, 2001, 35 (06) : 805 - 810
  • [34] Effect of long-term lamivudine in chronic hepatitis B virus-infected children
    Ozgenç, F
    Arikan, C
    Sertoz, RY
    Nart, D
    Aydogdu, S
    Yagci, RV
    ANTIVIRAL THERAPY, 2004, 9 (05) : 729 - 732
  • [35] Serum hepatitis B surface antigen monitoring in long-term lamivudine-treated hepatitis B virus patients
    Gramenzi, A.
    Loggi, E.
    Micco, L.
    Cursaro, C.
    Fiorino, S.
    Galli, S.
    Gitto, S.
    Galli, C.
    Furlini, G.
    Bernardi, M.
    Andreone, P.
    JOURNAL OF VIRAL HEPATITIS, 2011, 18 (10) : E468 - E474
  • [36] Evolution of hepatitis B virus precore/basal core promoter gene in HBeAg-positive chronic hepatitis B patients receiving lamivudine therapy
    Lin, CL
    Liao, LY
    Wang, CS
    Chen, PJ
    Lai, MY
    Chen, DS
    Kao, JH
    LIVER INTERNATIONAL, 2004, 24 (01) : 9 - 15
  • [37] Efficacy of lamivudine in patients with hepatitis B e antigen-negative hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B
    Tassopoulos, NC
    Volpes, R
    Pastore, G
    Heathcote, J
    Buti, M
    Goldin, RD
    Hawley, S
    Barber, J
    Condreay, L
    Gray, DF
    HEPATOLOGY, 1999, 29 (03) : 889 - 896
  • [38] Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B
    Hadziyannis, SJ
    Papatheodoridis, GV
    Dimou, E
    Laras, A
    Papaioannou, C
    HEPATOLOGY, 2000, 32 (04) : 847 - 851
  • [39] Lowest serum hepatitis B virus DNA level is predicable factor for viral breakthrough during lamivudine therapy in chronic hepatitis B patients
    Cho, M
    Heo, J
    Lyn, DY
    Cho, BM
    Kim, HH
    Kim, GH
    Kang, DH
    Song, GA
    Yang, US
    JOURNAL OF HEPATOLOGY, 2004, 40 : 126 - 126
  • [40] Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B
    Sokal, EM
    Kelly, DA
    Mizerski, J
    Badia, IB
    Areias, JA
    Schwarz, KB
    Vegnente, A
    Little, NR
    Gardener, SD
    Jonas, MM
    HEPATOLOGY, 2006, 43 (02) : 225 - 232
12345